Back to results

Treating Heart Dysfunction Related to Cancer Therapy with Sacubitril/Valsartan (Treat HF)

Objective

To determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 with stage B heart failure.

Protocol #

MCC-21-18830

Trial Phase:

Phase I/II

Principal Investigator:

Bottinor, Wendy

Cancer Type
  • Breast
  • Lung
  • Lymphoid Leukemia
  • Non-Hodgkin's Lymphoma
  • Stomach
Study Site
  • Stony Point
  • Virginia Commonwealth University

- Age </= 39 years old at time of cancer diagnosis
- Clinical records adequate to determine diagnosis and treatment regimen
- Previous anthracycline chemotherapy
- Global longitudinal strain <18% and/or
- LVEF below the institutional lower limit of normal but >/=40% on echocardiogram or cardiac MRI
- No symptoms of heart failure (shortness of breath, fatigue, swelling). Ordinary physical activity
does not cause undue fatigue, palpitation, dyspnea (shortness of breath).

Get more detailed information at ClinicalTrials.gov

  • Enrollment Status 1
  • Age Group Adult
  • Protocol Type Supportive Care
  • Research Study Team Tyler Phillips
    Email Study Contact

Click "I'm Interested" to get started. If you have questions, call our study contact.

I'm Interested
Have a question? We're here to help.

Email us or call us with your request.

Send an Email ยป (804) 628-6430
Share: